Angelini Pharma announced today the acquisition of Arvelle Therapeutics, the Swiss-based biopharmaceutical company focused on bringing innovative treatments to patients suffering from central nervous system disorders.
Following the acquisition of Arvelle Therapeutics, Angelini Pharma will have the exclusive license to commercialize cenobamate in the European Union, in Switzerland and in the United Kingdom.
Cenobamate has been designated as Promising Innovative Medicine by the UK’s drug agency (MHRA) for the treatment of drug-resistant focal-onset seizures in adults. Cenobamate is a small molecule with a unique dual complementary mechanism of action.
It acts positively modulating the γ-aminobutyric acid (GABAA) ion channel and inhibiting voltage-gated sodium currents. Key study's findings documented cenobamate’s clinical efficacy by showing a significant greater reduction in median seizure frequency and more patients achieving a 50% or greater reduction in seizure frequency compared to the placebo group. Cenobamate is approved by the Food and Drug Administration (FDA) in the United States as an anti-seizure medication (ASM) for the treatment of partial-onset (focal-onset) seizures in adults, and is available under the brand name XCOPRI® (cenobamate tablets) CV.
Angelini Pharma is planning to launch cenobamate after receiving European Medicines Agency (EMA)'s approval, expected in 2021.
This acquisition will propel Angelini Pharma into a leading European player, well positioned to address the needs of patients with different CNS and mental disorders through an innovative portfolio, distinctive medical capabilities and extensive commercial presence.